Retevmo Demonstrates Superior Progression-Free Survival for Adults with Newly-Diagnosed Non-Small Cell Lung Cancer

INDIANAPOLIS, Aug. 4, 2023. Eli Lilly and Company today announced topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed– with or without pembrolizumab– as an initial treatment...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials